» Articles » PMID: 33613617

Identification of a Metastasis-Associated Gene Signature of Clear Cell Renal Cell Carcinoma

Overview
Journal Front Genet
Date 2021 Feb 22
PMID 33613617
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Clear cell renal cell carcinoma (ccRCC) is one of the most frequent pathological subtypes of kidney cancer, accounting for ~70-75%, and the major cause of mortality is metastatic disease. The difference in gene expression profiles between primary ccRCC tumors and metastatic tumors has not been determined. Thus, we report integrated genomic and transcriptomic analysis for identifying differentially expressed genes (DEGs) between primary and metastatic ccRCC tumors to understand the molecular mechanisms underlying the development of metastases. The microarray datasets GSE105261 and GSE85258 were obtained from the Gene Expression Omnibus (GEO) database, and the R package limma was used for DEG analyses. In summary, the results described herein provide important molecular evidence that metastatic ccRCC tumors are different from primary tumors. Enrichment analysis indicated that the DEGs were mainly enriched in ECM-receptor interaction, platelet activation, protein digestion, absorption, focal adhesion, and the PI3K-Akt signaling pathway. Moreover, we found that DEGs associated with a higher level of tumor immune infiltrates and tumor mutation burden were more susceptible to poor prognosis of ccRCC. Specifically, our study indicates that seven core genes, namely the collagen family (COL1A2, COL1A1, COL6A3, and COL5A1), DCN, FBLN1, and POSTN, were significantly upregulated in metastatic tumors compared with those in primary tumors and, thus, potentially offer insight into novel therapeutic and early diagnostic biomarkers of ccRCC.

Citing Articles

Comprehensive analysis of signaling lymphocyte activation molecule family as a prognostic biomarker and correlation with immune infiltration in clear cell renal cell carcinoma.

Song N, Wang Z, Shi P, Cui K, Fan Y, Zeng L Oncol Lett. 2024; 28(2):354.

PMID: 38881710 PMC: 11176890. DOI: 10.3892/ol.2024.14487.


Activating transcription factor 3 is a new biomarker correlation with renal clear cell carcinoma progression.

Yang Z, Hou Y, Li J, Xu D, Yang Z, Wang X Int J Immunopathol Pharmacol. 2024; 38:3946320241227320.

PMID: 38248871 PMC: 10804930. DOI: 10.1177/03946320241227320.


Identification and Validation of the Prognostic Panel in Clear Cell Renal Cell Carcinoma Based on Resting Mast Cells for Prediction of Distant Metastasis and Immunotherapy Response.

Su Y, Zhang T, Lu J, Qian L, Fei Y, Zhang L Cells. 2023; 12(1).

PMID: 36611973 PMC: 9818872. DOI: 10.3390/cells12010180.


Case report and literature review: Small bowel intussusception due to solitary metachronous metastasis from renal cell carcinoma.

Yang W, Cai Z, Nie P, Yuan T, Zhou H, Du Q Front Oncol. 2023; 12:1072485.

PMID: 36601471 PMC: 9806257. DOI: 10.3389/fonc.2022.1072485.


Systematic identification of key extracellular proteins as the potential biomarkers in lupus nephritis.

Zhou X, Zhang Y, Wang N Front Immunol. 2022; 13:915784.

PMID: 35967373 PMC: 9366080. DOI: 10.3389/fimmu.2022.915784.


References
1.
Smoot M, Ono K, Ruscheinski J, Wang P, Ideker T . Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2010; 27(3):431-2. PMC: 3031041. DOI: 10.1093/bioinformatics/btq675. View

2.
Hsieh J, Chen D, Wang P, Marker M, Redzematovic A, Chen Y . Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol. 2016; 71(3):405-414. PMC: 5431298. DOI: 10.1016/j.eururo.2016.10.007. View

3.
de Lange Davies C, Engesaeter B, Haug I, Ormberg I, Halgunset J, Brekken C . Uptake of IgG in osteosarcoma correlates inversely with interstitial fluid pressure, but not with interstitial constituents. Br J Cancer. 2001; 85(12):1968-77. PMC: 2363997. DOI: 10.1054/bjoc.2001.2180. View

4.
Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello M . Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2005; 366(1):2-16. DOI: 10.1016/j.gene.2005.10.018. View

5.
Fisher R, Rosenberg S, Fyfe G . Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000; 6 Suppl 1:S55-7. View